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Recent studies have demonstrated the safety and efficacy of ocular gene therapy based
on adeno-associated viral vectors (AAVs). Accordingly, a surge in promising new gene
therapies is entering clinical trials, including the first optogenetic therapy for vision
restoration. To date, optogenetic therapies for vision restoration target either the retinal
ganglion cells (GCs) or presynaptic ON-bipolar cells (OBCs). Initiating light responses at
the level of the OBCs has significant advantages over optogenetic activation of GCs. For
example, important neural circuitries in the inner retina, which shape the receptive fields
of GCs, remain intact when activating the OBCs. Current drawbacks of AAV-mediated
gene therapies targeting OBCs include (1) a low transduction efficiency, (2) off-target
expression in unwanted cell populations, and (3) a poor performance in human tissue
compared to the murine retina. Here, we examined side-by-side the performance of
three state-of-the art AAV capsid variants, AAV7m8, AAVBP2, and AAV7m8(Y444F) in
combination with the 4xGRM6-SV40 promoter construct in the healthy and degenerated
mouse retina and in human post-mortem retinal explants. We find that (1) the 4xGRM6-
SV40 promoter is not OBC specific, (2) that all AAV variants possess broad cellular
transduction patterns, with differences between the transduction patterns of capsid
variants AAVBP2 and AAV7m8 and, most importantly, (3) that all vectors target OBCs
in healthy tissue but not in the degenerated rd1 mouse model, potentially limiting the
possibilities for an OBC-targeted optogenetic therapy for vision restoration in the blind.
Keywords: optogenetic vision recovery, bipolar cells, gene therapy, AAV vectors, human retina, rd1 mouse model,
rd10 mouse model, expression pattern analysis
INTRODUCTION
Blindness caused by photoreceptor degeneration affects approximately 1 in 3000 people world-
wide. Since the inner retinal layers typically remain intact after photoreceptor loss, novel
optogenetic therapies have aimed to recover light sensitivity in the inner retina through exogenous
expression of light sensitive ion channels. When introduced to the retinal ganglion cells (GCs) or
ON-bipolar cells (OBCs) of blind rd1 mice, Channelrhodopsin-2 (ChR2) restored light sensitivity
and basic levels of visual processing (Bi et al., 2006; Lagali et al., 2008; Doroudchi et al., 2011).
The first Phase I\IIa clinical trial on human patients (NCT02556736), which targets at delivering
ChR2 to GCs, was launched in 2016. In parallel, the unnaturally high light intensities required
for ChR2 activation have spurred the development of novel optogenetic tools based on more
van Wyk et al. ON-Bipolar Cell Targeted Gene Therapy
light-sensitive mammalian proteins (Cehajic-Kapetanovic et al.,
2015; van Wyk et al., 2015a). These next-generation optogenetic
therapies target the OBCs and re-activate the native OBC
signaling cascade. Therapies that target OBCs have the advantage
that they can re-activate early-stage processing of visual
information within the inner retina. It is also at the level of the
bipolar cells that incoming visual information is divided into
ON- and OFF-pathways, which might be imperative for visual
perception in higher visual centers (Thyagarajan et al., 2010). In
mammals, the retina contains multiple ON- and OFF-types of
cone bipolar cells and a single ON-type rod bipolar cell (RBC).
Since the RBC signal diverges into cone ON- and OFF-pathways
via the AII amacrine cell, optogenetic activation of OBCs restores
responses in both, the ON- and OFF-pathways (Macé et al., 2015;
van Wyk et al., 2015a).
Adeno-associated viral (AAV) vectors were proven to be
powerful gene delivery vehicles to the photoreceptors and GCs;
however, efficient transduction of the inner nuclear layer (INL),
including the OBCs, has been a challenge. Novel AAV capsid
variants generated by in vivo directed evolution in the mouse
retina, including AAV7m8 (Dalkara et al., 2013), AAV8BP2
(Cronin et al., 2014) and Y-to-F mutations on the AAV2
capsid (Doroudchi et al., 2011) were shown to reach the inner
retina. A short 200-bp GRM6 enhancer sequence combined
with the viral SV40 basal promoter is typically used to restrict
optogene expression to OBCs (Kim et al., 2008). In order to
increase transgene expression, Cronin and colleagues probed the
efficacies of multiple copies of the 200-bp enhancer cassette and
found optimal expression when using four enhancer elements in
tandem (4xGRM6-SV40; Cronin et al., 2014).
While novel AAV variants perform well in mice, species-
specific differences and individual differences in retinal
degeneration can potentially result in different patterns of
transgene expression. That is, an AAV vector that performs well
in a wild-type mouse retina may not have the same efficacy in
a degenerating retina or in the retina of a human. To address
this concern, we evaluated the three most promising AAV
capsid variants, AAV8BP2 (Cronin et al., 2014), AAV7m8
(Dalkara et al., 2013) and the single Y-F point mutant
thereof, AAV7m8(Y444F) (Lu et al., 2016), side-by-side
in two mouse models of photoreceptor degeneration—rd1
and rd10—and in human retinal explants. The goal was
to characterize the cellular expression patterns of the OBC
optogenetic designer tool, Opto-mGluR6 (van Wyk et al.,
2015a) after intravitreal AAV injection, which is the preferred
application method in the clinic since it is less invasive than a
subretinal injection and does not bear the risk of retinal tears or
detachment.
We find that the 4xGRM6-SV40 promoter is notOBC specific,
that all AAV variants possess a broad cellular transduction
pattern in all systems, with differences between the AAV7m8 and
AAVBP2 capsids as well as differences between the expression
in murine and human retinas, and, most importantly, that all
vectors target OBCs in healthy tissue but not in the degenerated
rd1 mouse model. Our study emphasizes the need to employ
animal and human disease models for promoter and AAV
development in light of a successful future clinical application.
RESULTS
In light of the ongoing efforts to develop an OBC-based gene
therapy for optogenetic vision restoration, this study aimed to
investigate side-by-side the OBC transduction efficacies of three
state-of-the-art AAV capsid variants in healthy and degenerating
mouse retinas and in human retinal explants. We equipped all
viral vectors with the OBC-specific 4xGRM6-SV40 promoter
(Cronin et al., 2014) and the Opto-mGluR6 designer optogene
(van Wyk et al., 2015a) linked via an IRES sequence to the
mCitrine fluorescent reporter gene.
Cell-Type Specificity in the WT Mouse
Retina
We first assessed the overall abilities of AAV7m8 and AAVBP2
to mediate gene delivery to the wild-type C57/BL6 mouse
retina. Intravitreal injection of both capsid variants resulted
in strong pan-retinal mCitrine expression that was visible 3
weeks post-injection using in vivo fluorescence fundus imaging
(Figures 1A–C). Although transduction was observed across
the retina, we often found more extensive labeling around
the optic nerve, in the peripheral retina and along large
blood vessels. There were no overall quantitative or qualitative
differences in the transgene expression patterns between retinas
treated with AAV7m8 and AAVBP2 vectors that lie outside
the variation observed between retinas within each treatment
group (n ≥ 20 retinas per treatment group). To examine
the cellular expression profiles in more detail, we labeled
retinal wholemounts (Figures 1D–F) and vertical cryosections
(Figures 2, 3) immunohistochemically against mCitrine. Despite
the use of the “OBC-specific” 4xGRM6-SV40 promoter, mCitrine
expression was not restricted to OBCs in retinas transfected with
either of the AAV capsids. In addition to OBC labeling, treated
retinas showed extensive mCitrine labeling in the amacrine
cell layer, and weaker labeling in the GC layer (Figures 2,
3, 4E,F). In AAV7m8 treated retinas, we observed off-target
expression of mCitrine in a single homogenous and evenly
spaced amacrine cell type (Figures 2A,C). We identified these
amacrine cells morphologically as AII amacrine cells based
on their lobular processes in the OFF-sublamina of the IPL,
their extensive dendritic arbors in the ON-sublamina including
multiple close contacts with the axon terminals of PKCα-positive
RBCs (Figure 2G) and their strong reactivity to an antibody
against Glycine Transporter 1 (GLYT1; Figure 2H). Compared
to AAV7m8, AAVBP2 labeled significantly more glycinergic
amacrine cells (GLYT1-positive cells; P= 0.0045; Table 1), which
appear morphologically different (Figures 3A,C,G). AAVBP2
also labeled a bright plexus of wide-field amacrine cells with
long beaded dendrites that stratify in the center of the IPL
(Figures 3A,D,H) and occasionally, B-Type horizontal cells
(Figure S1).
To identify the transduced bipolar cell types, we performed
triple staining against mCitrine, Gγ13 (labels all OBCs)
and PKCα (specific for RBCs). Although the 4xGRM6-SV40
promoter was expected to equally mediate expression in cone
OBCs and in RBCs, the AAV7m8 capsid almost exclusively
labeled RBCs (95.0 ± 1.8% RBCs vs. 5.0 ± 1.8% cone OBCs;
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FIGURE 1 | Intravitreal injections of AAV7m8 and AAVBP2 into wild-type mice mediate panretinal expression of Opto-mGluR6_IRES_mCitrine under
the 4xGRM6-SV40 promoter. (A–C) Retinal in-vivo fundus fluorescence imaging of a control eye (A), and eyes injected with AAV7m8 (B), and AAVBP2 (C),
respectively, 3 weeks post injection. The retinas of the treated eyes show a large overall increase in fluorescence, with individual fluorescent cells often visible as bright
specks. (D,E) Laser scanning micrographs of AAV7m8 (D) and AAVBP2 (E) treated retinal whole-mounts where mCitrine was labeled immunocytochemically. Despite
more intense staining in some regions, mCitrine labeled cells are seen in all areas. (F) A higher magnification of the region indicated by the broken square in (D).
Table 1; Figure 2F). AAVBP2 transduced significantly more cone
OBCs compared to AAV7m8 (P = 0.02), however, expressing
cells were still predominantly RBCs (82.1± 11.3 % RBCs vs. 17.9
± 11.3% cone OBCs; Table 1; Figure 3F).
Since it was shown that the Y444F point mutation on the
AAV7m8 capsid improves the overall transgene expression and
also enables expression in cone OBCs (Lu et al., 2016), we
probed mCitrine expression when using the AAV7m8(Y444F)
capsid (n = 6 eyes). In our hands AAV7m8(Y444F) did not
enhance expression nor did it cause any changes in cellular
tropism compared to AAV7m8, with no significant difference in
the percentage of mCitrine-labeled OBCs that were also PKCα
positive (P = 0.5; Table 1; Figure 2I). Again, expression was
almost exclusively restricted to RBCs and AII amacrine cells with
some GC labeling. Since we observed no effective differences
between the AAV7m8 and the AAV7m8(Y444F) capsids, we did
not further investigate the tropism of AAV7m8(Y444F) in the
mouse retina.
Cellular Tropism in the Degenerating
Mouse Retina
Multiple studies have described morphological and physiological
changes in the inner retina after photoreceptor degeneration.
Some of these changes include a retraction of bipolar cell
dendrites and synaptic rewiring (Strettoi and Pignatelli, 2000;
Jones et al., 2012), the generation of rhythmic oscillations in the
inner retina (Menzler and Zeck, 2011) and changes in protein
expression and trafficking (Puthussery et al., 2009; Xu et al.,
2012). It is therefore not justified to assume that the activities
of promoters and AAV capsids remain unaffected when the
photoreceptors degenerate. Accordingly, we next investigated the
cellular transduction patterns of AAV7m8 and AAVBP2 in the
most commonly used mouse model of retinal degeneration, the
Pde6brd1 (rd1) mouse (Chang et al., 2002; vanWyk et al., 2015b).
In the rd1 mouse, degeneration starts with a fast onset of rod
dystrophy at postnatal day (P) 8–10, followed by a peak in rod
degeneration at P14 and a near complete loss of rods and RBC
dendrites by P21. Degeneration of the rod system is marked by
a total loss of scotopic ERG responses in the 4th week of life. A
secondary degeneration of cones starts in the 5th week of life and
the dendrites of the cone bipolar cells retract. The main peak of
cone degeneration is in the 7th–8th week of life; however, a single
row of cone photoreceptors persists up to the age of 6 months
(Farber et al., 1994; Hackam et al., 2004; van Wyk et al., 2015b).
In a first round we injected strongly degenerated, 4-month-
old rd1 mice intravitreally with each capsid type (n = 8 eyes
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FIGURE 2 | Intravitreal injection of AAV7m8 in wild-type mice primarily expresses Opto-mGluR6_IRES_mCitrine in RBCs and AII amacrine cells when
using the 4xGRM6-SV40 promoter. (A) Transverse cryosection of an AAV7m8-treated retina with staining against PKCα (red, marker for RBCs) and mCitrine
(green). Primarily two cell populations are labeled including the RBCs and a second layer of cell bodies in the amacrine cell (AC) layer. (B–E) Optical en-face sections
of retinal whole-mounts labeled against PKCα and mCitrine taken at different depths from the same area using the same laser microscope settings. (B) Bipolar cell
layer: most rod RBCs express mCitrine, with virtually no labeling in cells negative for PKCα. (C) Amacrine cell (AC) layer, a mosaic of brightly transduced cell bodies
(green) and the axons of the RBCs (red) are seen. (D) Inner border of the inner plexiform layer (IPL), the fuzzy green background indicates the dendrites of the labeled
ACs between the RBC terminals in red. (E)Weak mCitrine staining can be seen in some GCs. The secondary anti-mouse Cy3 antibody also labels blood vessels (red).
(F) Triple labeling against mCitrine (blue), PKCα (green), and Gγ13 (red) confirms that transduced BPCs are largely RBCs (yellow) with nearly no labeling in cone OBCs
that express Gγ13 but no PKCα (red; marked by arrowheads). (G) The labeled ACs (green) have the AII AC morphology with lobular processes in the OFF-sublamina
of the IPL and more extensive dendritic arbors in the ON-sublamina including multiple close contacts with the axon terminals of PKCα-positive RBCs (red). (H) The
amacrine cells expressing mCitrine (green) show GLYT1 reactivity (red) in the membranes of their cell bodies and their lobular processes in the OFF-sublamina. The
insert shows a magnification of the broken square. (I) A micrograph with the same labeling as in (F) but treated with AAV7m8 (Y444F) instead of AAV7m8. The staining
patter is similar, with mCitrine staining primarily restricted to RBCs and a single layer of ACs.
per capsid). Similar to wild-type retinas, we removed rd1 retinas
after a 4-week viral incubation period and probed mCitrine
expression. Surprisingly, while the labeling of glycinergic
amacrine cells remained unaffected in these rd1 retinas, the
mCitrine signal in RBCs was nearly completely abolished
(Figures 4G,H). We also observed no labeling of wide-field
amacrine cells or B-Type horizontal cells in AAVBP2 treated
rd1 retinas. These results suggest substantial changes in the gene
expression profile of the degenerating retina.
As both, AAV7m8 and AAVBP2 vectors almost exclusively
target RBCs, which remodel within the 4th postnatal week and in
this process potentially downregulate expression from the GRM6
enhancer (Puthussery et al., 2009), we additionally injected a
second group of rd1 mice shortly after weaning (3.5 weeks old;
n = 6 eyes per capsid). The transduction patterns in these
younger rd1mice remained, however, identical to older rd1mice
with lacking expression in OBCs. The loss of OBC labeling in rd1
retinas resulted in a significantly higher fraction of labeled cells
expressing GLYT1 both in AAV7m8 (P < 0.0001) and AAVBP2
(P < 0.0001) treated rd1 retinas compared to wild-type retinas
(Figures 4A–D; Table 1; n≥ 6 micrographs collected from n≥ 4
retinas).
To investigate this phenomenon in more detail, we probed
AAVBP2-mediated expression in an alternative, slower
degenerating mouse model, the Pde6brd10 (rd10) mouse.
The rd10 mouse has a missense mutation in exon 13 of the
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FIGURE 3 | Intravitreal injection of AAVBP2 in wild-type mice primarily
expresses Opto-mGluR6_IRES_mCitrine in RBCs and several types of
amacrine cells under the 4xGRM6-SV40 promoter. (A) A cryosection
labeled against PKCα (red) and mCitrine (green). Primarily two layers of cell
bodies are labeled, RBCs and ACs with sparser labeling of GCs. The arrow
shows a bright layer of dendrites in the middle of the IPL. (B–E) Optical
en-face sections taken at different depths using the same laser microscope
settings from the same area stained for PKCα (red) and mCitrine (green). (B)
Bipolar cell layer: most RBCs express mCitrine. mCitrine labeling is, however,
also seen in cell bodies not positive for PKCα. Horizontal cell processes can
also be seen on this micrograph (arrows). (C) Amacrine cell layer: many cell
bodies are labeled and
(Continued)
FIGURE 3 | Continued
the axons of RBCs are seen in red. (D) Middle of the IPL: a network of long
beaded dendrites from wide-field amacrine cells is visible. (E) Weak mCitrine
staining can be seen in some cell bodies in the GC layer. The secondary
anti-mouse Cy3 antibody also labels the blood vessels (red). (F) Triple labeling
against mCitrine (blue), PKCα (green), and Gγ13 (red) shows that transfected
BPCs are largely RBCs (yellow) with nearly no labeling in cone OBCs that
express Gγ13 but no PKCα (marked by arrow heads). The only weakly labeled
cone OBC is indicated by a red arrow. (G) Most of the amacrine cells labeled
in AAVBP2 retinas (green) express GLYT1 (red) in their cell membranes. (H)
Example of a brightly labeled wide-field amacrine cell that projects long
beaded dendrites to the center of the IPL (green).
same Pde6b gene affected in rd1 mice resulting in partial Pde6b
activity. Compared to rd1mice, the onset of degeneration is later
at P18 and the progression slower (Gargini et al., 2007). The
scotopic ERG is lost in postnatal week 8, indicating complete loss
of rods and remodeling of RBCs (Gargini et al., 2007; van Wyk
et al., 2015b). We therefore injected 11-week-old rd10mice (n =
6 eyes) with a degenerative state approximately corresponding
to 4-week-old rd1 mice. Unexpectedly, the cellular expression
pattern in rd10 mice was similar to that observed in wild-type
C57/BL6 retinas, with high levels of RBC labeling (Figures 4I,J).
It is important to note that, after the viral incubation period of
4 weeks, degeneration in the now 8-week-old rd1 retinas might
be more severe compared to the rd10 mice, which we sacrificed
at the age of 15 weeks. The results may imply that 4xGRM6-
SV40 promoter driven gene expression is downregulated in a
phenotype dependent manner.
Cellular Tropism in the Human
Post-Mortem Retinal Explant
Due to numerous anatomic and physiologic differences between
the eyes of mice and “men,” we evaluated the transduction
characteristics of all three capsids, AAV7m8, AAV7m8(Y444F),
and AAVBP2 in post-mortem human retinal explants. We
prepared and treated explants from a total of five donor eyes.
After 7 days in culture, a homogenous mCitrine expression
became clearly visible, with some enhanced expression at the
edges of the explants, around blood vessels as well as in damaged
areas, likely due to better tissue access of the AAVs. Besides
some thinning of the retinal layers the explants remained well
preserved during culturing.
Similar to the mouse retina, the 4xGRM6-SV40 promoter
was not OBC-specific and led to broad transgene expression
throughout the explants (Figure 5). There were some clear
differences in the cellular transduction patterns in human tissue
compared to the mouse retina: Cone OBCs were transduced
equally well as RBCs (Figure 6; Table 1), a significant number of
photoreceptors also expressed the transgene and the three capsids
showed identical cellular tropism (Figure 5). About 90% of Goα-
positive cells expressed the transgene, independent of the AAV
capsid used (Table 1). The same percentage values were found for
transgene expressing PKCα-positive cells (Table 1), suggesting
that RBCs and cone OBCs were targeted equally well by all
capsids. Since viral incubation was limited to 7 days andmCitrine
was expressed behind an IRES motif designed for low expression
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FIGURE 4 | AAV7m8 and AAVBP2 expression patterns in degenerating mouse lines. (A,B) rd1 mice injected with AAV7m8 at the age of 3.5 weeks show in
hardly any mCitrine signal (green) in OBCs labeled with Gγ13 (A; red), while most mCitrine positive cells express GLYT1 (B; red). (C,D) As in (A,B), rd1 mice injected
(Continued)
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FIGURE 4 | Continued
with AAVBP2 at the age of 3.5 weeks show little mCitrine expression in OBCs (C) compared to glycinergic amacrine cells (D). (E–H) Intensity profiles of mCitrine
expression in AAV7m8 (E) and AAVBP2 (F) treated wild-type retinas and in rd1 AAV7m8 (G) and AAVBP2 (H) treated retinas. In (E,F) the mCitrine profiles (green)
show three clear peaks in the GC/IPL, AC and BC layers. For reference, the PKCα signal is indicated in red, with two peaks indicating the cell bodies and axon
terminals of the RBCs. Each figure shows the intensity profiles of six micrographs taken from three retinas (broken lines). The averaged signals are indicated in bold.
(G,H) Analog intensity profiles of mCitrine expression in rd1 retinas treated with AAV7m8 (G) and AAVBP2 (H). The mCitrine signals in BCs are markedly reduced in
the rd1 retinas. (I,J) In the rd10 retina AAVBP2 labels both, BPCs, and ACs similar to the wild-type retina. A large fraction of mCitrine-labeled cells (green) in the rd10
retina express PKCα (I; red) and Goα (J; red).
TABLE 1 | Cell counts in mouse and human retinas.
(cloned from the pIRES2 plasmid), only one of our mCitrine
antibodies gave strong enough staining for evaluation in human
explants. As this antibody was raised in a rabbit host, we were not
able to triple label mCitrine, PKCα and Gγ13/Goα (see Antibody
table). Therefore, staining against Gγ13 and PKCα were used
to determine the fraction of RBCs within the OBCs population
in individual explants, which ranged from 78% to 90%. These
fractions were then used to estimate the percentage of transgene
expressing cone OBCs in the respective explant. On average, this
percentage was calculated to be ∼97% for both, AAV7m8 and
AAVBP2-transduced explants (n = 3 retinas per capsid variant;
Table 1). To further verify high expression levels in cone OBCs,
we also transduced explants from the fovea centralis, which is
virtually devoid of rods and RBCs. Again, we observed high
numbers of transfected OBCs, confirming good transduction of
cone OBC with AAV7m8 and AAVBP2 in the human retina
(Figure 6).
In all explants, independent of the capsid used, we observed
off-target transgene expression in photoreceptor cells, in some
GCs and in Goα-negative cells, presumably amacrine cells, in the
INL (Figure 5). For all capsids, ∼69% of cells labeled in the INL
were not OBCs (n= 2 retinas per capsid variant; Table 1).
DISCUSSION
Retinal OBCs make attractive targets for optogenetic vision
restoration. Potential therapies targeting OBCs demand
efficient and specific optogene delivery and expression. Here,
we examined the abilities of the newly engineered AAV
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FIGURE 5 | Transduction patterns of AAV7m8, AAVBP2, and AAV7m8 (Y444F) in human retinal explants. (A–F) Vertical cryosections of human retinal explants
transduced with AAV7m8 (A,B), AAVBP2 (C,D), and AAV7m8 (Y444F) (E,F) were labeled with antibodies against mCitrine (green) and Goα (A,C,E, red) or PKCα
(B,D,F, red). A similar expression pattern is observed in retinas treated with all three capsids: Opto-mGluR6_IRES_mCitrine is preferentially expressed in the INL, with
high expression in OBCs (Goα-positive cells) but also in Goα-negative cells. (G,H)Whole-mount images at the level of the INL of explants treated with AAV7m8 (G) and
AAVBP2 (H) stained for mCitrine (green) and PKCα (red). (I,J) Intensity profiles of mCitrine expression in AAV7m8 (I) and AAVBP2 (J) treated explants. For reference,
the PKCα signal is indicated in red. mCitrine profiles (green) show a similar distribution, with a large peak in the INL and a second large peak in the ONL which
gradually increases toward the outer ONL. A double peak in the INL shows labeling both in the AC layer (first peak) and in the BC layer (second peak). Each figure
shows the intensity profiles of 4 images taken from immune-labeled transverse cryosections of two explants (broken lines). The averaged signals are indicated in bold.
capsid variants AAV7m8, AAVBP2, and AAV7m8(Y444F) in
combination with the state-of-the-art “OBC specific” 4xGRM6-
SV40 promoter (Kim et al., 2008; Cronin et al., 2014; van
Wyk et al., 2015a) to deliver the optogenetic designer tool
Opto-mGluR6 to retinal OBCs. Due to the known anatomic
and physiologic differences between healthy and degenerating
retinas and between the retinas of mice and humans, we
compared reporter expression patterns in both healthy and
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FIGURE 6 | Cone OBCs near the fovea centralis express the transgene in human retinal explants transduced with AAV7m8 and AAVBP2. (A–F) Vertical
cryosections of human retinal explants transduced with AAV7m8 (A–C) or AAVBP2 (D–F). (A,D) Labeling against Goα (red) and mCitrine (green) near the fovea
centralis shows transgene expression in OBCs. (B,E) Labeling against PKCα (red) and Gγ13 (green) of the same regions of neighboring sections to (A) and (D) show
that no cells in this region were labeled by PKCα, confirming their cone OBC identity. (C,F) In comparison to (B,E), sections from the mid-periphery show a high
fraction of Gγ13-positive cells (green), which also express PKCα (red). OBCs not positive for PKCα are indicated by arrows.
degenerating mouse retinas and in post-mortem human retinal
explants.
We first tested the capsids side-by-side in the wild-type
C57/BL6 mouse retina. The three capsid variants penetrated
equally well to the INL. However, despite the identical enhancer-
promoter used in all capsids, AAVBP2 and AAV7m8 showed a
different cell-type specific transduction pattern. Although both
capsids had a preference for RBCs and amacrine cells, AAVBP2
showed a wider tropism. A preference of AAV7m8(Y444F)
for RBCs over cone OBCs was previously shown (Lu et al.,
2016). In our hands, AAV7m8 and AAV7m8(Y444F) showed a
virtually identical, non-specific transduction pattern. All viruses
mediated significant off-target labeling in the mouse and human
retinas, particularly of glycinergic amacrine cells and, most
strikingly, none of the viruses were able to transduce OBCs in
the degenerated rd1 retina.
As the AAV capsids were titer-matched to the minimal
dose that efficiently transduces cells in the INL (Cronin
et al., 2014), we conclude that the 4xGRM6-SV40 promoter,
and consequently also the GRM6-SV40 promoter, are not
“OBC specific” promoters as commonly believed. Recently, an
endogenous murine Grm6 promoter variant has been developed
that was reported to reduce off-target expression compared to the
GRM6-SV40 promoter (Lu et al., 2016). The non-specificity of
the 4xGRM6-SV40 promoter, however, allowed us to differentiate
between the cellular transfection patterns of each capsid variant
andmost importantly, it allowed us to compare OBC transfection
in wild-type and degenerating retinas using off-target expression
as an internal reference.
We showed for the first time a clear qualitative difference in
AAV-driven expression in the commonly used rd1mouse model
of rod dystrophy compared to the wild-type mouse. In all rd1
retinas transduced with AAV7m8 or AAVBP2, the OBCs showed
hardly any reporter expression. Since we still observed OBC
expression in rd10 retinas, we hypothesize that the 4xGRM6-
SV40 promoter is downregulated in late stages of photoreceptor
degeneration. Since the cones are lost in a secondary stage of
degeneration and cone OBCs were shown to remain responsive
to glutamate until∼P180 (Puthussery et al., 2009), AAV variants
that have the ability to transduce cone OBCs are favored when
treating rod dystrophy. Likewise, promoters based on alternative
OBC-specific genes, which are not downregulated during retinal
degeneration, might be preferable. These considerations have
to be taken into account when developing a therapy aimed
at restoring vision in patients suffering from photoreceptor
degeneration.
Previous studies, however, were able to record light responses
from GCs in the rd1 retina treated with AAV-based gene
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therapies, using both the 1x and 4xGRM6-SV40 promoters
(Cronin et al., 2014; Macé et al., 2015; van Wyk et al., 2015a).
One possible explanation for functional recovery is that low-
level optogene expression in OBCs suffices to drive weak light
responses in rd1 retinas. As we show here, OBC labeling in the
rd1 retina is strongly downregulated but not completely absent.
Also, we cannot exclude the possibility that light responses
were, at least in part, driven by off-target cells. One of the
studies, however, demonstrated OBC-specific ChR2 expression
anatomically in rd1 mice of similar age as used in this study
(Macé et al., 2015). The basis for this discrepancy is not obvious.
One possibility is phenotype-dependent downregulation of the
GRM6-SV40 promoter with progressing degeneration. We have
previously demonstrated that secondary genetic factors affect the
phenotype of degeneration in different rd1 strains (vanWyk et al.,
2015b), potentially also affecting the activity of the GRM6-SV40
promoter; Macé and colleagues used the C3H/HeN rd1 mouse
line, whereas we used the C3H/HeOu line. The 1xGRM6-SV40
promoter has also been used to introduce ChR2 into the OBCs
of the rd1 retina by electroporation of new-born mouse pups
(Lagali et al., 2008). It is difficult, however, to relate the expression
achieved with electroporation of neonatal mice with that of an
AAV-based gene therapy in adult mice.
For a more clinically relevant comparison we also tested the
transduction patterns in post-mortem human retinal explants.
In these experiments transduction was wide-spread and similar
for all capsid variants contrasting previous studies that reported
successful transduction of human explants only in the parafoveal
region and along blood vessels (Sengupta et al., 2016). In line
with the fact that the morphology of the eyes of mouse and
human differ, the overall cell transduction pattern differed, with
marked expression in the photoreceptor cells of human explants.
Remarkably, the cellular transduction pattern was virtually
identical to that reported for the unspecific CMV promoter
(Cronin et al., 2014).
We found no overall quantitative difference between
AAV7m8, AAVBP2, and AAV7m8(Y444F) mediated transgene
expression in the human retina. The high levels of transduction,
including off-target photoreceptor labeling, may be attributed
to the increased “viral pressure,” as AAV solutions were directly
applied to the explants allowing optimal access of the virus to the
cells. The distinct differences between the expression patterns
in human retinal explants and the murine retina show that the
actions of the viral vectors and/or the 4xGRM6-SV40 promoter
are species-dependent.
Off-target expression using a “leaky” promoter such as
4xGRM6-SV40 may not always be a disadvantage. In general,
there exist two therapeutic approaches that target OBCs, the
first using ChR2 or variants thereof (Lagali et al., 2008; Macé
et al., 2015) and a second using Gi-coupled photopigments that
feed into the native mGluR6 signaling cascade of the OBCs,
rendering their function OBC specific (Cehajic-Kapetanovic
et al., 2015; van Wyk et al., 2015a). In the mouse, AAV7m8
almost exclusively transduces two cell types, the RBCs and the
AII amacrine cells, making it a suitable tool for either approach.
When using ChR2, the light-activated depolarizing drive of the
RBCs is relayed to the AII amacrine cells that will now be
equally depolarized, potentially increasing the drive of the cone
ON- and OFF-bipolar cells. Additional transduction of GCs,
although relatively weak, will perturb the visual signal when
ChR2 variants are used since all GCs that express ChR2 will
depolarize in response to light, corrupting the OFF-channel.
This may not be a problem when Gi-coupled optogenetic
tools are used, as GCs are less likely to generate a large
response due to a lack of matching intracellular signaling
components. The extensive tropism of AAVBP2, including the
transduction of wide-field amacrine cells and horizontal cells,
may compromise visual resolution when combined with a ChR2
variant. Again, for Gi-coupled optogenetic tools this may not be
an issue.
Our study emphasizes the need to employ animal and
human disease models when advancing of optogenetic treatment
strategies targeted at the inner retina.
MATERIALS AND METHODS
AAV Vectors
The OBC-specific mouse 4xGRM6 enhancer sequence (see
below) in combination with the viral SV40 basal promoter
(Cronin et al., 2014) was PCR amplified (F: 5′-TAT AGC TAG
CAC GCG TGA TCT CCA GAT GGC TAA AC, R: 5′-TAT
AAG ATC TAA GCT TTA TAG GAT CCG GTA CCT TTG
CAA AAG CCT AGG CC) from the pAAV-4xGRM6-CatCh-
EGFP plasmid (received from B. Roska under an MTA by the
Friedrich Miescher Institute for Biomedical Research, Basel,
Switzerland), cut with BglII and NheI and inserted into a
linearized pAAV-Rho-EGFP vector (kind gift from A. Auricchio)
(Allocca et al., 2007) that was cut with BamHI and NheI
(BamHI and BglII have compatible overhangs) to create the
pAAV-4xGRM6-SV40 plasmid. Opto-mGluR6_IRES_mCitrine
(van Wyk et al., 2015a) was inserted between the HindIII
and BamHI restriction sites of the pAAV-4xGRM6-SV40
plasmid using an In-Fusion 2.0 homologous recombination Kit
(Clontech). Viral vectors were produced in AAV-293 cells by
triple plasmid co-transfection. We co-transfected the pAAV-
4xGRM6-SV40_Opto-mGluR6_IRES_mCitrine expression
plasmid, the AAV-helper plasmid encoding Rep2 and Cap for
serotype variants, and the pXX680 plasmid harboring helper
adenoviral genes (kindly provided by H. Büning) using the
calcium-phosphate precipitation method. Empty virions were
removed by density purification over an iodixanol gradient
(Axis-Shield, Oslo) and the 40% iodixanol fraction subsequently
buffer exchanged by amicon filtration (Millipore). The AAV
fraction was titered for DNase-resistant vector genomes by
real-time PCR relative to a standard vector. The AAV7m8
capsid plasmid was a kind gift from D. Dalkara and the
BP2 capsid plasmid was a kind gift from T. Cronin. The
AAV7m8(Y444F) capsid plasmid was generated by site-directed
point mutagenesis (QuikChange kit) on the AAV7m8 Rep2-Cap
plasmid. Vectors were stored at −80◦C until just before use.
To allow for a direct comparison, we titer-matched all AAV
variants in sterile PBS to 1.8 × 1012 genome copies ml−1 before
injection.
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Complete sequence of the 4xGRM6-SV40 Promoter
ACGCGTGATC TCCAGATGGC TAAACTTTTA AATCAT
GAAT GAAGTAGATA TTACCAAATT GCTTTTTCAG CAT
CCATTTA GATAATCATG TTTTTTGCCT TTAATCTGTT
AATGTAGTGA ATTACAGAAA TACATTTCCT AAATCAT
TAC ATCCCCCAAA TCGTTAATCT GCTAAAGTAC ATCT
CTGGCT CAAACAAGAC TGGTTGCTCG ACATTGATTA
TTGACTAGTG ATCTCCAGAT GGCTAAACTT TTAAATC
ATG AATGAAGTAG ATATTACCAA ATTGCTTTTT CAGCA
TCCAT TTAGATAATC ATGTTTTTTG CCTTTAATCT GTTA
ATGTAG TGAATTACAG AAATACATTT CCTAAATCAT
TACATCCCCC AAATCGTTAA TCTGCTAAAG TACATC
TCTG GCTCAAACAA GACTGGTTGC TCGACATTGA TTA
TTGACTA GTGATCTCCA GATGGCTAAA CTTTTAAATC
ATGAATGAAG TAGATATTAC CAAATTGCTT TTTCAGC
ATC CATTTAGATA ATCATGTTTT TTGCCTTTAA TCTGT
TAATG TAGTGAATTA CAGAAATACA TTTCCTAAAT CAT
TACATCC CCCAAATCGT TAATCTGCTA AAGTACATCT
CTGGCTCAAA CAAGACTGGT TGCTCGACAT TGATTAT
TGA CTAGTGATCT CCAGATGGCT AAACTTTTAA ATCA
TGAATG AAGTAGATAT TACCAAATTG CTTTTTCAGC
ATCCATTTAG ATAATCATGT TTTTTGCCTT TAATCTG
TTA ATGTAGTGAA TTACAGAAAT ACATTTCCTA AATC
ATTACA TCCCCCAAAT CGTTAATCTG CTAAAGTACA
TCTCTGGCTC AAACAAGACT GGTTGCTCGA GATCTG
CGAT CTGCATCTCA ATTAGTCAGC AACCATAGTC CCG
CCCCTAA CTCCGCCCAT CCCGCCCCTA ACTCCGCCCA
GTTCCGCCCA TTCTCCGCCC CATCGCTGAC TAATTT
TTTT TATTTATGCA GAGGCCGAGG CCGCCTCGGC
CTCTGAGCTA TTCCAGAAGT AGTGAGGAGG CTTTT
TTGGA GGCCTAGGCT TTTGCAAAAA GCTT
Gray highlights indicate four tandem repeats of the enhancer
sequence and “bold letters” indicate the SV40 promoter.
Animals and Injections
We obtained C57Bl/6J from breeding stock at the Jackson
Laboratory (Bar Harbor, ME) and C3H/HeOu (rd1) and
B6.CXB1-Pde6brd10/J (rd10) mice from breeding stocks at the
Charles River Laboratories (Sulzfeld, Germany). All animal
experiments and procedures were reviewed and approved by
the Swiss Veterinary Office. All injections were performed
by the same skilled person. Wild type mice were injected at
an age between 4 and 6 weeks, the age of injection of the
different degenerating treatment groups are specified in the
Results Section: rd1 mice were injected at 3.5 and 16 weeks
of age, rd10 mice at 11 weeks of age. Mice were anesthetized
by intraperitoneal injection of 100 mg/kg ketamine and 10
mg/kg xylazine. We then punctured the sclera on the nasal
side ∼1 mm from the corneal limbus using a 30G needle.
The puncture needle was removed, and a 33G blunt needle
was maneuvred through the hole to the back of the eye (RPE
injection kit from World Precision Instruments). We then
injected 2 µl of titer-matched virus (1.8 × 1012 GC ml−1)
solution into the vitreous and waited for 20 s before retracting
the injection needle form the eye. Following surgery, the eyelids
were stuck closed using petroleum jelly to prevent drying of the
cornea.
Human Post-Mortem Retinal Explants
All procedures were in compliance with governmental
regulations and in accordance with the tenets of the Declaration
of Helsinki. The Swiss Ethics Committee has reviewed this study
and exempted it from the ethics review process. As per national
laws and regulations [Federal Act on Research involving Human
Beings (Human Research Act, HRA 810.30, Art. 38)], no ethics
approval is required for this type of study. Anonymized tissue
was provided by the Department of Ophthalmology, Inselspital,
Bern University Hospital, Switzerland. Preparation of human
retinal explants was performed as previously described (Fradot
et al., 2011). After removal of the cornea, eyes were stored in cold
phosphate-buffered saline (PBS). Post-mortem delay times for
explanting never exceeded 20 h. Immediately after receiving the
eyes, the retina was isolated and transferred to HEPES buffered
Ames’ medium containing Gentamicin (50 µg/mL; Arman and
Sampath, 2010). Retinal fragments of ∼0.5 cm2 were prepared
from the mid-periphery of the retina (8–15 mm distal from
the macula) and the macula (see Figure S2) and transferred
with the GC layer facing up on to Millicell hanging cell culture
inserts (12-well, PET, 0.4 µm, Merck Millipore, PIHT15R48).
The explants were incubated in R16 medium with supplements
(Romijn, 1988) for 2 h prior to AAV administration. We placed
5 µl of AAV solution (1.8× 1012 GCml−1) directly on top of the
explants. After 1 day, 200 µl of fresh medium was added to each
culture followed by a daily exchange of 350 µl of medium until
fixation on day 7 of culturing.
In vivo Fundus Imaging of Mouse Retinas
Transduction was assessed in vivo by recording the mCitrine
signal using confocal scanning laser ophthalmoscopy (Spectralis
OCT, Heidelberg Engineering GmbH, Heidelberg, Germany).
Imaging in anaesthetized mice was performed in blue light (488
nm) autofluorescence mode using a non-contact ultra-widefield
102◦ lens. The mice were placed on a custom-made platform
for optimal alignment of the eye with the optical axis of the
imaging device, and corneas were protected from desiccation
with hydroxypropylmethylcellulose (Methocel 2%, OmniVision,
Neuhausen, Switzerland). The large vessels were brought into
focus in near infrared mode, and a slight further adjustment
to re-focus was made after switching to autofluorescence
mode to compensate for wave-length dependent differences in
refraction.
Immunohistochemistry
We removed mouse retinas 4 weeks post-injection for
immunohistochemical analysis. Mouse eyes and human retinal
explants were fixed with 4% (wt/vol) paraformaldehyde in PBS
for 40min at room temperature (RT), cryoprotected over three
consecutive nights at 4◦C in graded sucrose solutions (10%, 20%,
and 30% sucrose in PBS), embedded in cryomolds with O.C.T.
compound (Sakura Finetek), and frozen in liquid nitrogen-
cooled 2-methylbutane. Vertical sections of 10 µm thickness
were cut on a cryostat, mounted on SuperFrost glass slides
(Menzel) and stored at −20◦C until use. O.C.T. was removed by
placing slides in PBS for 5 min. The sections were subsequently
lined with an oil pen and covered in blocking solution (6%
vol:vol normal goat or donkey serum, depending on the
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Name Host/Class Company Catalog No. Dilution
Anti GFP Rabbit/Polyclonal Invitrogen A11122 1:500
Anti GFP Chicken/Polyclonal Abcam ab13970 1:500
Anti PKCα Mouse/Monoclonal Santa Cruz Biotechnology sc8393 1:750
Anti Goα Mouse/Monoclonal EMDMillipore MAB3073 1:750
Anti Gγ13 Rabbit/Polyclonal Santa Cruz Biotechnology sc368324 1:500
anti GLYT1 Rabbit/Polyclonal antibodies-online ABIN1841935 1:500
Anti-Rabbit Alexa Fluor 488 Goat/Polyclonal Invitrogen A11008 1:400
Anti-Mouse Cyanine 3 Goat/Polyclonal Invitrogen A10521 1:400
Anti-Rabbit Alexa Fluor 488 Donkey/Polyclonal Invitrogen A21206 1:400
Anti-Chicken Cyanine 5 Donkey/Polyclonal Jackson Immuno-Research Laboratories 703-175-155 1:400
Anti-Rabbit Alexa Fluor 594 Goat/Polyclonal Invitrogen A11037 1:400
secondary antibodies used, 2% wt:vol bovine serum albumin, and
0.1% vol:vol TritonX-100 in PBS) for 45 Min at RT. Primary
and secondary antibodies (see Antibody table) were diluted in
50% blocking solution in PBS containing either normal goat or
donkey serum (depending on the secondary antibodies). Primary
antibodies were applied over night at 4◦C, followed by three
washes in PBS at RT. Secondary antibodies together with DAPI
(1:180 dilution of 0.1 mg/mL stock solution, Sigma Aldrich) were
applied for 2 h at RT. Fixed whole-mount retinas were incubated
over night at 4◦C in blocking solution, primary antibodies were
applied for 6 days at 4◦C and secondary antibodies together with
DAPI for 5 days at 4◦C. Whole-mount retinas and sections were
mounted on slides with DAKO Fluorescence Mounting Medium
(Agilent Technologies).
Microscopy and Image Analysis
A ZEISS LSM 880 with Airyscan and ZEN 2.1 software was used
to take confocal images using either a 20x or 40x objective lens.
Images were imported to Fiji (Schindelin et al., 2012) for image
processing and cell counting.
Statistics
Microsoft Excel was used for all statistical calculations. We
performed two-tailed Student’s t-tests to determine significant
differences between groups. Data were expressed as the mean
± standard deviation (SD). Different levels of significance are
indicated by ∗ for P < 0.05, ∗∗ for P < 0.01, and ∗∗∗ for P < 0.001.
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Figure S1 | AAVBP2-treated wild-type mouse retinas show sporadic
labeling of B-Type horizontal cells. (A–D) Examples of B-Type horizontal cells
labeled in AAVBP2-treated retinas. In order to demonstrate the classic B-Type
horizontal cell morphology, micrographs were taken from areas with low overall
levels of transfection where background fluorescence was minimal. Axons are
indicated by arrows.
Figure S2 | (A) Regions of the human retina used for explant culturing.
Explants of ∼0.5 cm2 were prepared from the mid-periphery (indicated in
red) or the macula (indicated in blue). (B,C) Whole-mount images of
explants treated with AAV7m8 (B) and AAVBP2 (C) stained for mCitrine
(green), PKCα (red) and DAPI (blue). Both explants were from the
mid-periphery, indicated by the red band in (A).
REFERENCES
Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo,
M., et al. (2007). Novel adeno-associated virus serotypes efficiently transduce
murine photoreceptors. J. Virol. 81, 11372–11380. doi: 10.1128/JVI.01327-07
Arman, A. C., and Sampath, A. P. (2010). Patch clamp recordings from mouse
retinal neurons in a dark-adapted slice preparation. J. Vis. Exp. 43:e2107.
doi: 10.3791/2107
Bi, A., Cui, J., Ma, Y., Olshevskaya, E., Pu, M., Dizhoor, A., et al.
(2006). Ectopic expression of a microbial-type rhodopsin restores visual
responses in mice with photoreceptor degeneration. Neuron 50, 23–33.
doi: 10.1016/j.neuron.2006.02.026
Cehajic-Kapetanovic, J., Eleftheriou, C., Allen, A., Milosavljevic, N., Pienaar,
A., Bedford, R., et al. (2015). Restoration of vision with ectopic expression
of human rod opsin. Curr. Biol. 25, 2111–2122. doi: 10.1016/j.cub.2015.
07.029
Frontiers in Neuroscience | www.frontiersin.org 12 March 2017 | Volume 11 | Article 161
van Wyk et al. ON-Bipolar Cell Targeted Gene Therapy
Chang, B., Hawes, N., Hurd, R., Davisson, M., Nusinowitz, S., and Heckenlively,
J. (2002). Retinal degeneration mutants in the mouse. Vision Res. 42, 517–525.
doi: 10.1016/S0042-6989(01)00146-8
Cronin, T., Vandenberghe, L., Hantz, P., Juttner, J., Reimann, A., Kacsó, A., et al.
(2014). Efficient transduction and optogenetic stimulation of retinal bipolar
cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol.
Med. 6, 1175–1190. doi: 10.15252/emmm.201404077
Dalkara, D., Byrne, L., Klimczak, R., Visel, M., Yin, L., Merigan, W., et al. (2013).
In vivo-directed evolution of a new adeno-associated virus for therapeutic
outer retinal gene delivery from the vitreous. Sci. Transl. Med. 5, 189ra176.
doi: 10.1126/scitranslmed.3005708
Doroudchi, M., Greenberg, K., and Liu, J. (2011). Virally delivered
Channelrhodopsin-2 safely and effectively restores visual function in multiple
mouse models of blindness.Mol. Ther. 19, 1220–1229. doi: 10.1038/mt.2011.69
Farber, D., Flannery, J., and Bowes-Rickman, C. (1994). The rd mouse story:
seventy years of research on an animal model of inherited retinal degeneration.
Prog. Retin. Eye Res. 13, 31–64. doi: 10.1016/1350-9462(94)90004-3
Fradot, M., Busskamp, V., Forster, V., Cronin, T., Léveillard, T., Bennett, J., et al.
(2011). Gene therapy in ophthalmology: validation on cultured retinal cells
and explants from postmortem human eyes. Hum. Gene Ther. 22, 587–593.
doi: 10.1089/hum.2010.157
Gargini, C., Terzibasi, E., Mazzoni, F., and Strettoi, E. (2007). Retinal organization
in the retinal degeneration 10 (rd10) mutant mouse: a morphological and ERG
study. J. Comp. Neurol. 500, 222–238. doi: 10.1002/cne.21144
Hackam, A., Strom, R., Liu, D., Qian, J., Wang, C., Otteson, D., et al. (2004).
Identification of gene expression changes associated with the progression
of retinal degeneration in the rd1 mouse. Invest Ophthalmol. Vis. Sci. 45,
2929–2942. doi: 10.1167/iovs.03-1184
Jones, B., Kondo, M., Terasaki, H., Lin, Y., McCall, M., andMarc, R. (2012). Retinal
remodeling. Jpn. J. Ophthalmol. 56, 289–306. doi: 10.1007/s10384-012-0147-2
Kim, D. S., Matsuda, T., and Cepko, C. L. (2008). A core paired-type
and POU homeodomain-containing transcription factor program
drives retinal bipolar cell gene expression. J. Neurosci. 28, 7748–7764.
doi: 10.1523/JNEUROSCI.0397-08.2008
Lagali, P., Balya, D., Awatramani, G., Münch, T., Kim, D., Busskamp,
V., et al. (2008). Light-activated channels targeted to ON bipolar cells
restore visual function in retinal degeneration. Nat. Neurosci. 11, 667–675.
doi: 10.1038/nn.2117
Lu, Q., Ganjawala, T., Ivanova, E., Cheng, J., Troilo, D., and Pan, Z. (2016). AAV-
mediated transduction and targeting of retinal bipolar cells with improved
mGluR6 promoters in rodents and primates. Gene Ther. 23, 680–689.
doi: 10.1038/gt.2016.42
Macé, E., Caplette, R., Marre, O., Sengupta, A., Chaffiol, A., Barbe, P., et al. (2015).
Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered
AAV Restores, O. N., and OFF visual responses in blind mice. Mol. Ther. 23,
7–16. doi: 10.1038/mt.2014.154
Menzler, J., and Zeck, G. (2011). Network oscillations in rod degenerated
mouse retinas. J. Neurosci. 31, 2280–2291. doi: 10.1523/JNEUROSCI.4238-
10.2011
Puthussery, T., Gayet-Primo, J., Pandey, S., Duvoisin, R., and Taylor, W. (2009).
Differential loss and preservation of glutamate receptor function in bipolar
cells in the rd10 mouse model of retinitis pigmentosa. Eur. J. Neurosci. 29,
1533–1542. doi: 10.1111/j.1460-9568.2009.06728.x
Romijn, H. (1988). Development and advantages of serum-free, chemically
defined nutrient media for culturing of nerve tissue. Biol. Cell 63, 263–268.
doi: 10.1016/0248-4900(88)90116-5
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat.
Methods 9, 676–682. doi: 10.1038/nmeth.2019
Sengupta, A., Chaffiol, A., Macé, E., Caplette, R., Desrosiers, M., Lampicˇ, M., et al.
(2016). Red-shifted channelrhodopsin stimulation restores light responses in
blind mice, macaque retina, and human retina. EMBOMol .Med. 8, 1248–1264.
doi: 10.15252/emmm.201505699
Strettoi, E., and Pignatelli, V. (2000). Modifications of retinal neurons in a mouse
model of retinitis pigmentosa. Proc. Natl. Acad. Sci. U.S.A. 97, 11020–11025.
doi: 10.1073/pnas.190291097
Thyagarajan, S., van Wyk, M., Lehmann, K., Löwel, S., Feng, G., and Wässle,
H. (2010). Visual function in mice with photoreceptor degeneration and
transgenic expression of channelrhodopsin 2 in ganglion cells. J. Neurosci. 30,
8745–8758. doi: 10.1523/JNEUROSCI.4417-09.2010
van Wyk, M., Pielecka-Fortuna, J., Löwel, S., and Kleinlogel, S. (2015a). Restoring
the ON-switch in blind retinas: Opto-mGluR6, a next-generation, cell-
tailored optogenetic tool. PLoS Biol. 13:e1002143. doi: 10.1371/journal.pbio.10
02143
van Wyk, M., Schneider, S., and Kleinlogel, S. (2015b). Variable phenotypic
expressivity in inbred retinal degeneration mouse lines: a comparative study
of C3H/HeOu and FVB/N rd1 mice.Mol. Vis. 21, 811–827.
Xu, Y., Dhingra, A., Fina, M., Koike, C., Furukawa, T., and Vardi, N.
(2012). mGluR6 deletion renders the TRPM1 channel in retina inactive. J.
Neurophysiol. 107, 948–957. doi: 10.1152/jn.00933.2011
Conflict of Interest Statement: The Department of Ophthalmology receives
research support from Heidelberg Engineering, and some members of the team
are consultants to Heidelberg Engineering.
Copyright © 2017 van Wyk, Hulliger, Girod, Ebneter and Kleinlogel. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Neuroscience | www.frontiersin.org 13 March 2017 | Volume 11 | Article 161
